My Portfolio
+
LINK YOUR PORTFOLIO

Vera Therapeutics, Inc VERA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 5:02 PM EDT
31.72quote price arrow up+0.45 (+1.44%)
Volume
25,760
Close
31.27quote price arrow up+0.01 (+0.03%)
Volume
948,247
52 week range
19.07 - 56.05
Loading...
  • Open31.26
  • Day High31.71
  • Day Low30.59
  • Prev Close31.26
  • 52 Week High56.05
  • 52 Week High Date12/24/25
  • 52 Week Low19.07
  • 52 Week Low Date08/07/25

Key Stats

  • Market Cap2.245B
  • Shares Out71.78M
  • 10 Day Average Volume0.99M
  • Dividend-
  • Dividend Yield-
  • Beta0.95

KEY STATS

  • Open31.26
  • Day High31.71
  • Day Low30.59
  • Prev Close31.26
  • 52 Week High56.05
  • 52 Week High Date12/24/25
  • 52 Week Low19.07
  • 52 Week Low Date08/07/25
  • Market Cap2.245B
  • Shares Out71.78M
  • 10 Day Average Volume0.99M
  • Dividend-
  • Dividend Yield-
  • Beta0.95

RATIOS/PROFITABILITY

  • EPS (TTM)-5.54
  • P/E (TTM)-5.65
  • Fwd P/E (NTM)-5.75
  • EBITDA (TTM)-382.888M
  • ROE (TTM)-71.32%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)15.01%

EVENTS

  • Earnings Date08/03/2026(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Vera Therapeutics, Inc. is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain...
Michael Morrissey Ph.D.
Independent Chairman of the Board
Marshall Fordyce M.D.
President, Chief Executive Officer, Founder, Director
David Johnson
Chief Operating Officer
Sean Grant
Chief Financial Officer
Address
2000 Sierra Point Parkway, Suite 1200
Brisbane, CA
94005
United States